Skip to content

the effect of duloxetine on theanxiety and depression of patients with diabetic neuropathy

Investigation of the effect of duloxetine on the mental state of patients with diabetic neuropathy (anxiety / depression)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210725051977N2
Enrollment
30
Registered
2022-04-07
Start date
2022-05-05
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Effect of Duloxetine on the Mental State of Patients (Anxiety) with Diabetic Neuropathy. Condition 2: Effect of Duloxetine on the Mental State of Patients (Depression) with Diabetic Neuropathy. Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy

Interventions

Intervention group: A group treated with duloxetine in the form of 30 mg oral capsules,Twice a day (every 12 hours) for 30 days.

Sponsors

Islamic Azad University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Age between 20 to 85 Diabetic patients with sensory diabetic neuropathy in organs with symptoms of anxiety or depression (ASA patients 1-3)

Exclusion criteria

Exclusion criteria: Lack of patient cooperation in proper drug use or response Drug intolerance by the patient Pregnant women

Design outcomes

Primary

MeasureTime frame
Determination mental state (anxiety / depression) of patients with diabetic neuropathy based on Beck questionnaire. Timepoint: Determining the score of anxiety and depression at the beginning of the study (before the intervention) and 30 days after taking duloxetine. Method of measurement: Beck Anxiety and Depression Inventory questionnaire.

Secondary

MeasureTime frame
Intensity of pain Fingers or toes based on VAS scale. Timepoint: Determining the score of anxiety and depression at the beginning of the study (before the intervention) and 30 days after taking Duloxetine. Method of measurement: Visual Analogue Scale.;Frequency of adverse drug complications (Duloxetine). Timepoint: 30 days after taking Duloxetine. Method of measurement: ?Check list including possible adverse drug reactions following Duloxetine.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoud Khoshbin

Islamic Azad University

masoudkhoshbin@iauyazd.ac.ir+98 35 3138 0155

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026